Literature DB >> 19262587

Can antiepileptic drugs unmask a susceptibility to psychiatric disorders?

Andres M Kanner1.   

Abstract

Psychiatric adverse events have been associated with rapid titration and high doses of most antiepileptic drugs (AEDs). However, several AEDs can cause such events at any dose. These agents include barbiturates, topiramate, levetiracetam and zonisamide. A search of the literature reveals that psychiatric adverse events associated with these AEDs seem not to occur at random. Rather, they are most likely to be reported by patients who have an inherent vulnerability to psychiatric disorders; that is, those with a personal or family history of psychiatric illness. In a recent study by Mula et al., patients who underwent rapid titration of topiramate had a fivefold increase in risk of depressive episodes. In patients with a history of depression, however, the risk increase was 23.3-fold. Thus, clinicians must ascertain a patient's personal and family psychiatric history before choosing an AED and planning the dose titration regimen.

Entities:  

Year:  2009        PMID: 19262587     DOI: 10.1038/ncpneuro1051

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  8 in total

1.  The role of titration schedule of topiramate for the development of depression in patients with epilepsy.

Authors:  Marco Mula; Dale C Hesdorffer; Michael Trimble; Josemir W Sander
Journal:  Epilepsia       Date:  2008-10-24       Impact factor: 5.864

2.  Psychiatric adverse events during vigabatrin therapy.

Authors:  D F Levinson; O Devinsky
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

3.  Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables.

Authors:  M R Trimble; N Rüsch; T Betts; P M Crawford
Journal:  Seizure       Date:  2000-06       Impact factor: 3.184

4.  Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.

Authors:  Marco Mula; Michael R Trimble; Josemir W Sander
Journal:  Epilepsia       Date:  2007-08-17       Impact factor: 5.864

5.  Phenobarbital treatment and major depressive disorder in children with epilepsy.

Authors:  D A Brent; P K Crumrine; R R Varma; M Allan; C Allman
Journal:  Pediatrics       Date:  1987-12       Impact factor: 7.124

6.  Psychiatric adverse events during levetiracetam therapy.

Authors:  M Mula; M R Trimble; A Yuen; R S N Liu; J W A S Sander
Journal:  Neurology       Date:  2003-09-09       Impact factor: 9.910

7.  Tiagabine: the safety landscape.

Authors:  I E Leppik
Journal:  Epilepsia       Date:  1995       Impact factor: 5.864

8.  A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events.

Authors:  Andres M Kanner; Joanne Wuu; Edward Faught; William O Tatum; Aaron Fix; Jacqueline A French
Journal:  Epilepsy Behav       Date:  2003-10       Impact factor: 2.937

  8 in total
  3 in total

Review 1.  Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations.

Authors:  John Piedad; Hugh Rickards; Frank M C Besag; Andrea E Cavanna
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

2.  Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study.

Authors:  J R White; T S Walczak; S E Marino; T E Beniak; I E Leppik; A K Birnbaum
Journal:  Neurology       Date:  2010-08-10       Impact factor: 9.910

3.  Acute mania associated with levetiracetam treatment.

Authors:  Eliza M Park; Jordan A Holmes; Katherine E Reeder-Hayes
Journal:  Psychosomatics       Date:  2013-08-09       Impact factor: 2.386

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.